Sponsor content
789 result(s) found, displaying 41 to 50
-
Australian Public Assessment Report (AusPAR)Dostiva and Dexeva are approved for preventing or managing cancer related bone complications and are biosimilars of Xgeva. Denolia and Deskeltia are approved for treating osteoporosis in men and postmenopausal women, as well as bone loss due to cancer therapies or long term glucocorticoid use and are biosimilars of Prolia.
-
Cancellation by sponsorRequested by Accord Healthcare Pty Ltd
-
Cancellation by sponsorRequested by Accord Healthcare Pty Ltd
-
Cancellation by sponsorRequested by Accord Healthcare Pty Ltd
-
CYTARABINE INTAS cytarabine 1000 mg/10 mL injection vial Cancelled under Section 30(1)(c) of the Act
Cancellation by sponsorRequested by Accord Healthcare Pty Ltd -
CYTARABINE INTAS cytarabine 5000 mg/50 mL injection vial Cancelled under Section 30(1)(c) of the Act
Cancellation by sponsorRequested by Accord Healthcare Pty Ltd -
CYTARABINE INTAS cytarabine 2000 mg/20 mL injection vial Cancelled under Section 30(1)(c) of the Act
Cancellation by sponsorRequested by Accord Healthcare Pty Ltd -
Cancellation by sponsorRequested by Accord Healthcare Pty Ltd
-
CYTARABINE INTAS cytarabine 4000 mg/40 mL injection vial Cancelled under Section 30(1)(c) of the Act
Cancellation by sponsorRequested by Accord Healthcare Pty Ltd -
Cancellation by sponsorRequested by Accord Healthcare Pty Ltd